Article
Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
Oncotarget - 18 Oct 2016
Ray Paramita, Tan Yee Sun, Somnay Vishal, Mehta Ranjit, Sitto Merna, Ahsan Aarif, Nyati Shyam, Naughton John P, Bridges Alexander, Zhao Lili, Rehemtulla Alnawaz, Lawrence Theodore S, Ray Dipankar, Nyati Mukesh K
Abstract excerpt
Non-small cell lung cancer (NSCLC) patients carrying specific EGFR kinase activating mutations (L858R, delE746-A750) respond well to tyrosine kinase inhibitors (TKIs). However, drug resistance develops within a year. In about 50% of such patients, acquired drug resistance is attributed to the enrichment of a constitutively active point mutation within the EGFR kinase domain (T790M). To date, differential...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.